Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders

NCT01379625 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT01379625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01379625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Lead sponsor
Oregon Health and Science University
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
April 30, 2015
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carnitine palmitoyltransferase 2 (cpt2) deficiency, long-chain 3 hydroxyacylcoa dehydrogenase (lchad) deficiency, mitochondrial trifunctional protein (tfp) deficiency, very long-chain acylcoa dehydrogenase (vlcad) deficiency